Q-omics provides the consensus-scored PHF24 profile across patient tissues and cancer cell-line models. PHF24 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PHF24 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PHF24 RNA expression shows 17,821 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where PHF24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHF24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHF24 survival associations across molecular data types. PHF24 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (7) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHF24 RNA expression–survival associations across cancer types. High PHF24 expression shows unfavorable associations in KIRP and LUAD, but favorable associations in UVM, PAAD, SKCM and ESCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PHF24 RNA expression.
This table summarizes PHF24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PHF24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHF24 shows lower tumor expression in THCA, UCEC, COAD, LUAD and BRCA and higher tumor expression in HNSC. The HNSC box plot shows higher PHF24 RNA expression in tumor versus normal tissue (log2 FC = +1.472, t-test p < 0.001).
This table shows molecular features associated with PHF24 in patient tissues and cancer cell lines. In patient samples, PHF24 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PHF24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
